Filing Flows › Embecta (EMBC) › Syringes revenue
Embecta (EMBC) Syringes revenue by quarter
Embecta's Syringes revenue was $36.6M in Q3 FY26 (third quarter fiscal 2026), +39% from Q2 FY26. Over the last 6 quarters it ranged from $26.3M (Q2 FY26) to $36.6M (Q3 FY26).
| Quarter | Syringes revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 FY26 | $36.6M | +39% | +4% |
| Q2 FY26 | $26.3M | -14% | -9% |
| Q1 FY26 | $30.7M | -5% | — |
| Q4 FY25 | $32.3M | -8% | — |
| Q3 FY25 | $35.1M | +22% | — |
| Q2 FY25 | $28.8M | — | — |
Q3 FY26 at a glance
Embecta, Q3 FY26: revenue $272M (-8% year over year), operating margin 17.9%, net earnings $21.1M, operating cash flow $41.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is Embecta's Syringes revenue?
Embecta's Syringes revenue was $36.6M in Q3 FY26 (third quarter fiscal 2026), +39% from Q2 FY26.
How has Embecta's Syringes revenue changed?
Over the last 6 quarters it ranged from $26.3M (Q2 FY26) to $36.6M (Q3 FY26).